


Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 066683-0190		SERIAL NO. 09/679,147	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Tomoki TODO et al.			
				FILING DATE 10/05/2000		GROUP ART UNIT 1632	

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
---------------------	-----	--------------------	------	------	-------	---------------	----------------------------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



				Katsanis, et al., B7-1 Expression decreases tumorigenicity and induces partial systemic immunity....., Cancer Gene Ther., 2:39-46, (1995)			
		A2		Katsanis et al, Irradiation of singly and doubly transduced murine neuroblastoma....., Cancer Gene Ther.3:75-82, (1996)			
		A3		Heuer et al.; Hum.Retrovirus-Mediated Gene Transfer of B7-1 and MHC Class II Gene Ther., 7:2059-2068, (1996)			
		A4		Kanner et al., CD2/LFA-3 Ligation induces phospholipase..... J. Immunol., 148:2023-9, No. 7, (1992)			
		A5		Kato et al., CD48 is a counter-receptor for Mouse CD2 and is involved in T Cell Activation, J. Exp. Med., 176:1241-9, (1992)			
		A6		Hurtado et al., Potential Role of 4-1BB in T Cell Activation..... J. Immunol., 155:3360-7, (1995)			
		A7		Noelle et al., A 39-kDa protein on activated helper T cells binds CD40 and Proc. Natl. Acad. Sci. USA, 89:6550-6554, (1992)			
		A8		Todo et al., In Situ Expression of Soluble B7-1 in the Context of Oncolytic Herpes Simplex..... Cancer Res., 61:, 153-161, (2001)			
		A9		Fry et al., Gene therapy: potential applications in clinical transplantation, Expert Reviews in molecular medicine, 1-24, ISSN 1462-3994 Cambridge University Press, 1462-3994 (1999)			
		A10		Roth et al., Gene Therapy for Cancer: What have we done and where are we going?, J. National Cancer institute, Vol. 89, No. 1, 21-39, (1997)			
		A11		Ye et al., Gene Therapy for Cancer using single-chain Fv fragments specific for 4-1BB, J. Nature Medicine , Vol. 8, 343-348, (2002)			

EXAMINER <i>Amodeo</i>	DATE CONSIDERED <i>6/10/02</i>
---------------------------	-----------------------------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.